Muscular Dystrophy Canada fund nine new projects through 2023 grant program
NMD4C Investigators involved in many of these exciting clinical and translational research projects
On Thursday March 30th, Muscular Dystrophy Canada (MDC) announced the results of their 2023 Neuromuscular Clinical and Translational Research Grant Program. A dedicated Canadian source of funding for neuromuscular research, this annual funding competition invests in clinical and translational research projects related to the diagnosis, treatment, or clinical care of neuromuscular disorders. These research grants help fill current gaps in the funding landscape.
This year we are pleased to celebrate the many NMD4C investigators and members who are leading and supporting MDC-funded projects! You can find the full list of funded projects on MDC’s website.
2023 Clinical Research Projects
Establishing the Top Ten Research Priorities for Respiratory Care of Childhood Neuromuscular Disorders ($50,000)
NMD4C investigators and collaborators as project co-investigators and collaborators
Dietary Protein Requirements in Adults with Muscular Dystrophy ($100,000)
Project Lead
Dr Tyler Churchward-Venne
McGill University
NMD4C member as project co-investigator
Dr Mark Tarnopolsky
Muscle MRI in neuromuscular disorders. The era of Artificial Intelligence ($100,000)
NMD4C investigator as project collaborator
B-FIT! Taking exercise away from the hospital into the home environment in people with Oculopharyngeal muscular dystrophy ($100,000)
Project Lead
Dr Eric Voorn
University of Amsterdam
NMD4C investigators and members as project co-investigators and collaborators
Reimagining Rehabilitation for SMA: Patient and Family Perspectives ($83,166)
Project Lead
Dr Jill Glennis Zwicker
University of British Columbia
NMD4C investigators and members as project co-investigators and collaborators
Translational Research Grants
Therapy development for centronuclear myopathy caused by DNM2 gene changes ($100,000)
How genealogies (family histories) can help us understand myotonic dystrophy type 1 ($99,600)
Project Lead
Dr Simon Girard
Université du Québec à Chicoutimi
NMD4C investigators as project co-investigators
Evaluating the impact of stop variants on MLIP’s (Muscular LMNA-Interacting Protein) function in muscle ($100, 000)
Pre-clinical testing of novel pharmacological inhibitors of toxic DMPK mRNA in models of myotonic dystrophy type 1 ($100 000)
Project Lead
Dr Pascal Chartrand
University of Montreal
Read next...
Zolgensma® Safety Update and CPNG Guidance for Families
The Canadian Pediatric Neuromuscular Group (CPNG) has issued a statement for families regarding recent reports of tumours in children treated with Zolgensma® (onasemnogene abeparvovec) gene therapy for spinal muscular atrophy (SMA). The statement outlines current evidence, considerations for follow-up care, and information for families and healthcare providers.
Could You Be Our Next Awardee? Meet Jules Granet, NMD4C’s 2026 Publication of the Year Awardee
Nominations are open till by 18 January 2027!
In 2026, Jules Granet, a PhD Candidate at McGill University and trainee in Dr. Natasha Chang’s laboratory received an NMD4C Publication of the Year Award for research investigating how muscle stem cell dysfunction contributes to impaired muscle regeneration in Duchenne muscular dystrophy. Nominate yourself or a neuromuscular colleague whose research, clinical care, leadership, advocacy, or community contributions deserve to be recognized.
Early Bird Registration Now Open: 8th Ottawa International Conference On Neuromuscular Disease & Biology
We are happy to announce that early bird registration is now open for the 8th Ottawa International Conference On Neuromuscular Disease & Biology which will be held on October 14-16, 2027 at the Fairmont Château Laurier in Ottawa, Canada. Now under the leadership of NMD4C Investigators; Dr. Mireille Khacho, Dr. Hanns Lochmuller, Dr. Bernard Jasmin, and Dr. Rashmi Kothary.